ClinicalTrials.gg
Not yet recruitingNCT07702955Updated Jul 21, 2026

Phase I Study of Single-Agent KGX105 in Patients With Advanced or Metastatic Solid Tumors

A Phase 1 interventional study of KGX105 injection in Advanced or Metastatic Solid Tumors, sponsored by Kangabio AUSTRALIA LTD PTY. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-21.

Sponsored by Kangabio AUSTRALIA LTD PTY · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
85
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a first-in-human, open-label, multicenter, Phase I study to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics (PK/PD), and preliminary antitumor activity of single-agent KGX105 in participants with locally advanced or metastatic solid tumors. The study consists of two parts: Phase 1a dose escalation and Phase 1b dose expansion.

02

Conditions studied

  • Advanced or Metastatic Solid Tumors
03

In context

Lead sponsor

Kangabio AUSTRALIA LTD PTY is the lead sponsor of 3 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female participants with age ≥18 years, at the time of signing the .
  2. Dose Escalation Phase (Phase Ia):

    Participants with or cytologically confirmed locally advanced or malignant solid tumors meeting any of the following conditions:

    • Have received prior standard systemic anti-tumor therapy recommended by current guidelines for their tumor type and stage, and experienced disease progression or unacceptable toxicity during or after treatment;
    • Have no effective standard therapy available at present;
    • Meet any of the following conditions rendering standard therapy unsuitable:

      • Presence of known standard to standard therapy for their tumor type; •② Prior discontinuation of standard therapy due to intolerable toxicity; •③ Explicit refusal to receive available standard therapy.
    • Priority: Non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), nasopharyngeal carcinoma (NPC), pancreatic cancer, and other EGFR-positive* solid tumors such as gastroesophageal junction adenocarcinoma, gastric cancer, and esophageal squamous cell carcinoma.
  3. Dose Expansion Phase (Phase Ib):

    • Cohort 1 (EGFR-positiveNSCLC):*
    • Participants with driver gene-positive NSCLC must have received approved targeted therapy for the identified driver gene unless contraindicated; treatment discontinuation must be due to disease progression or intolerable toxicity. Driver genes primarily include: EGFR exon 19 deletion, L858R mutation, or exon 20 insertion mutation.
    • Participants with EGFR protein overexpression or gene amplification in driver gene-negative NSCLC must have received platinum-based chemotherapy and anti-PD-(L)1 antibody therapy (concurrent or sequential), unless contraindicated; treatment discontinuation must be due to disease progression or intolerable toxicity.
    • Cohort 2 (EGFR-positiveHNSCC, NPC):*
    • HNSCC participants must have received and/or platinum-based chemotherapy (with or without cetuximab).
    • NPC participants must have received platinum-based chemotherapy, with or without anti-PD-(L)1 antibodies.
    • Cohort 3 (Other EGFR-positivesolid tumors):*
    • Pancreatic cancer, gastric cancer, gastroesophageal junction adenocarcinoma, and esophageal squamous cell carcinoma that have progressed after at least one line of standard therapy.
    • Definition of EGFR-positivein this study:* Includes any of the following: EGFR protein overexpression (EGFR IHC staining intensity ≥1+), EGFR gene mutation, or EGFR gene amplification (by NGS).
  4. According to 1.1, there must be at least one (tumor lesions located in a previously irradiated area or other sites of locoregional therapy generally are not considered measurable unless they have demonstrated clear progression or have persisted for three months after radiation therapy).

    Note: Metastatic brain lesions are not considered as target lesions.

  5. 0-1.
  6. of ≥3 months, in the opinion of the investigator.
  7. Adequate organ function as determined by medical evaluation including:

    • Adequate hematologic status, defined as: (ANC) ≥1.5×109/L, ≥90 g/L, ≥100×109/L. Platelet transfusions are not permitted within 7 days, red blood cell transfusions are not permitted within 14 days, hematopoietic growth factors are not permitted within 7 days (14 days for PEGylated G-CSF or erythropoietin) prior to obtaining these laboratory values.
    • Adequate hepatic function, defined as: serum ≤1.5× (in participants with known Gilbert's syndrome, TBIL ≤3×ULN with direct bilirubin ≤1.5×ULN), serum or AST ≤2.5×ULN (or ≤5.0×ULN for documented liver metastasis).
    • Adequate renal function, defined as: ≥60 mL/min (measured or calculated by Cockcroft and Gault equation).
    • Adequate coagulation profile, defined as (including if receiving anticoagulation therapy): (PT) \<1.5×ULN, activated partial thromboplastin time (APTT) \<1.5×ULN. If the participant is on anticoagulation therapy, must be on a stable dose of anticoagulant for ≥1 month prior to study treatment.
  8. Women of must have a negative serum pregnancy test within 7 days prior to treatment.
  9. Women of childbearing potential or male partners of women of childbearing potential must agree to use highly effective throughout the treatment period and for 4 months after the last dose.
  10. Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the ICF and in this study.

Exclusion criteria

Exclusion Criteria:

  1. Diagnosis of another within 5 years prior to the first dose, except for:

    • Curatively resected basal cell carcinoma of the skin, squamous cell carcinoma of the skin, and/or carcinoma in situ;
    • Localized prostate cancer or papillary thyroid carcinoma post curative resection.
  2. Presence of , spinal cord compression, symptomatic , or brain metastases requiring /antiepileptic drugs or showing radiographic progression within 4 weeks prior to enrollment.

    •Exception:Asymptomatic brain metastases, or those stable for >4 weeks post-treatment without requiring steroids/antiepileptics, with a single lesion ≤1.5 cm and total number of lesions ≤5, are allowed.

  3. History of allogeneic organ transplantation, peripheral hematopoietic stem cell transplantation, or bone marrow transplantation.
  4. Pregnant or breastfeeding women, or individuals planning to donate sperm/eggs during the study period (from ICF signing to 4 months after the last dose).

    •Note:Breastfeeding women may be enrolled if they agree to stop breastfeeding prior to dosing and have no intention of resuming.

  5. Any severe or uncontrolled systemic disease, including:

    1. Active bleeding or known bleeding diathesis;
    2. Cardiac dysfunction or cardiovascular disease, including any of the following:

      •Uncontrolled cardiac disease, such as congestive heart failure requiring treatment ( > Class II);

      •Uncontrolled hypertension (resting BP ≥160/100 mmHg);

      •Poorly controlled arrhythmias;

      • with >470 ms (female) or >450 ms (male) (QTcF = QT/RR¹/³), or congenital long QT syndrome;

      •Echocardiogram: (LVEF) ≤50%;

      •Acute myocardial infarction or unstable angina within 6 months prior to study entry;

    3. Uncontrolled diabetes mellitus or poor compliance with hypoglycemic agents;
    4. Other chronic diseases that, in the investigator's opinion, may compromise participant safety or preclude completion of the study.
  6. Active infections:

    1. Known (HIV) infection, Treponema pallidum (TP) infection;
    2. Active [i.e., HBsAg positive and HBV DNA >1000 copies/mL (or 200 IU/mL), or HBV DNA above the lower limit of detection (if the LLOQ at the site is >200 IU/mL)];
    3. Virus (HCV) infection (i.e., HCV antibody positive and HCV-RNA positive);
    4. Other active infections requiring systemic therapy within 2 weeks prior to the first dose.
  7. Inadequate recovery from any prior surgery, or major organ surgery (excluding core needle or vascular intervention) within 4 weeks prior to study drug administration.
  8. Receipt of any of the following treatments:

    A. Prior treatment with T-cell engager drugs containing CD3 antibodies. B. Within the respective or 5 half-lives (whichever is shorter) prior to the first dose: Chemotherapy, biotherapy, or immunotherapy within 4 weeks; targeted therapy, radiotherapy, endocrine therapy, or oral fluoropyrimidines within 2 weeks; anti-tumor traditional Chinese medicine within 1 week; nitrosoureas or mitomycin C within 6 weeks.

    C. Live or attenuated within 4 weeks prior to the first dose (inactivated vaccines are allowed).

    D. Diagnosis of immunodeficiency, receipt of therapy, or chronic systemic/enteral steroid therapy (>10 mg/day prednisone or equivalent).

    E. Interstitial pneumonia, pulmonary fibrosis, pneumoconiosis, drug-induced pneumonitis, radiation pneumonitis requiring steroids or other treatment, or a history of severe pulmonary function impairment/restrictive lung disease.

  9. Adverse events from prior anti-tumor therapy have not resolved to v6.0 Grade ≤1 (except for alopecia, peripheral neuropathy, ototoxicity, or stable endocrinopathies managed with hormone replacement).
  10. Known to the active ingredient or any of the product.
  11. History of immunotherapy-related adverse events ≥ Grade 3 or leading to treatment discontinuation.
  12. History of active disease likely to recur (e.g., SLE, RA, Crohn's, ulcerative colitis, vasculitis), except:

    • Clinically stable autoimmune thyroid disease;
    • Use of inhaled or topical corticosteroids (ocular, intra-articular, nasal) with daily dose equivalent to ≤10 mg prednisone;
    • Short-term corticosteroid use (≤7 days) for prophylaxis (e.g., contrast allergy);
    • Replacement therapy (e.g., thyroxine for hypothyroidism, insulin for diabetes, physiological steroid replacement for adrenal/pituitary insufficiency).
  13. Presence of symptomatic pleural, peritoneal, or pericardial effusion requiring paracentesis/drainage at screening.

    •(Exclusion applies if drainage/intracavitary therapy was performed more than once [i.e., ≥2 times] for any cavity within 14 days prior to the first dose).

  14. History of active tuberculosis within 1 year prior to enrollment.
  15. History of thrombotic events (arterial or venous) within 6 months prior to screening, including cerebrovascular accidents (e.g., hemorrhage, infarction), deep vein thrombosis (DVT), and pulmonary embolism (PE).

    • Exception:Catheter-related thrombosis due to PICC or port placement may be allowed if deemed stable, asymptomatic, or adequately treated with no bleeding risk by the investigator.
Terms in these criteria, in plain language(41)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
85 participants (estimated)

Study arms

  • Experimental
    KGX105 monotherapy-Dose level 1

    Drug: KGX105 injection

  • Experimental
    KGX105 monotherapy-Dose level 2

    Drug: KGX105 injection

  • Experimental
    KGX105 monotherapy-Dose level 3

    Drug: KGX105 injection

  • Experimental
    KGX105 monotherapy-Dose level 4

    Drug: KGX105 injection

  • Experimental
    KGX105 monotherapy-Dose level 5

    Drug: KGX105 injection

  • Experimental
    KGX105 monotherapy-Dose level 6

    Drug: KGX105 injection

  • Experimental
    KGX105 monotherapy-Dose level 7

    Drug: KGX105 injection

Interventions

  • DrugKGX105 injection

    KGX105 is an investigational EGFR×CD3 TCE prodrug engineered with masked binding domains to reduce on-target, off-tumor toxicity and systemic activation. It is selectively activated in the tumor microenvironment (TME) to target EGFR-positive tumors. An integrated albumin-binding domain prolongs systemic half-life, optimizing drug exposure and efficacy.KGX105 injection is a sterile, white or slightly yellow lyophilized powder, supplied at 10.0 mg/vial for single use.

06

What researchers measure

Primary outcomes

  1. Numbers of participants with adverse events(Phase Ia)

    AE will be collected to assess participants' safety after KGX105 monotherapy

    Time frame: From baseline to 30 days after the last dose administration.

  2. Incidence of Dose-Limiting Toxicities (DLTs) during the DLT observation period.(Phase Ia)

    DLT will be observed from start of the first priming dose of KGX105 until 21 days post the first target dose of KGX105

    Time frame: From Day1 after the first priming dose of KGX105 until 21 days post the first target dose of KGX105

  3. Number of participants with changes of clinical lab abnormalities(Phase Ia)

    Any changes in values of the clinical chemistry, hematology, coagulation and urinalysis will be evaluated

    Time frame: From screening until 90 days post the last dose administration

  4. The maximum tolerated dose of KGX105 monotherapy(Phase Ia)

    Time frame: From Day 1 post the first dosing until 21 days post the the first target dosing

  5. Objective Response Rate (ORR) of KGX105 monotherapy (Phase Ib)

    The ratio of participants assessed with complete response (CR) or partial response (PR) as a best overall response.

    Time frame: until progression or death,whichever came first, assessed up to 2 years

Secondary outcomes

  1. Maximum observed concentration (Cmax) of KGX105 following single and multiple doses

    Pharmacokinetic (PK) parameters

    Time frame: From pre-dose of the first dose of KGX105 treatment until Day 1 of the last dose.

  2. Objective Response Rate (ORR) of KGX105 monotherapy (Phase Ia)

    The ratio of participants assessed with complete response (CR) or partial response (PR) as a best overall response.

    Time frame: From Day 1 after the first dose of KGX105 till survival follow-up every 90 days post the last treatment.

  3. Disease Control Rate (DCR) of KGX105 monotherapy

    The ratio of subjects assessed with CR or PR or stable disease (SD) as a best overall response.

    Time frame: From Day 1 after the first dose of KGX105 till survival follow-up every 90 days post the last treatment.

  4. Duration of Response(DoR)of KGX105 monotherapy

    DoR defined as the time from first documented evidence of CR or PR until disease progression or death.

    Time frame: From Day 1 after the first dose of KGX105 till survival follow-up every 90 days post the last treatment.

  5. Progression-Free Survival (PFS) of KGX105 monotherapy

    PFS defined as the time from first dose to radiographic progression or death due to any cause

    Time frame: From Day 1 after the first dose of KGX105 till survival follow-up every 90 days post the last treatment.

  6. Overall Survival (OS) of KGX105 monotherapy

    OS defined as the time from first dose to death due to any cause

    Time frame: From Day 1 after the first dose of KGX105 till survival follow-up every 90 days post the last treatment.

  7. Immunogenicity- Anti-drug antibody (ADA)、Neutralizing Antibodies(Nab)

    Samples will be collected to assess the immunogeniccity after each KGX105 treatment.

    Time frame: Samples will be collected to assess the immunogeniccity after each KGX105 treatment.

  8. Numbers of participants with adverse events(Phase Ib)

    AE will be collected to assess participants' safety after KGX105 monotherapy

    Time frame: From baseline to 30 days after the last dose administration

  9. Number of participants with changes of clinical lab abnormalities(Phase Ib)

    Any changes in values of the clinical chemistry, hematology, coagulation and urinalysis will be evaluated

    Time frame: From screening until 90 days post the last dose administration

  10. Phase 2 dose (RP2D) of KGX105 monotherapy (Phase Ib)

    Time frame: From Day 1 after the first dose of KGX105 till survival follow-up every 90 days post the last treatment.

  11. Time to Cmax (Tmax)of KGX105 following multiple doses

    Pharmacokinetic (PK) parameters

    Time frame: From pre-dose of the first dose of KGX105 treatment until Day 1 of the last dose

  12. Area under the concentration-time curve from time zero to the last quantifiable concentration (AUC₀-ₜ), AUC from time zero extrapolated to infinity (AUC₀-∞)

    Pharmacokinetic (PK) parameters

    Time frame: From pre-dose of the first dose of KGX105 treatment until Day 1 of the last dose

  13. Elimination half-life (t₁/₂) of KGX105 following multiple doses

    Pharmacokinetic (PK) parameters

    Time frame: From pre-dose of the first dose of KGX105 treatment until Day 1 of the last dose

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Aug 2026; primary completion for Sep 2028, 25 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 2, 2026
First posted
Jul 14, 2026
StartEst.
Aug 2026
Primary completionEst.
Sep 2028
CompletionEst.
Nov 2028
Last update
Jul 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07702955
Lead sponsor
Kangabio AUSTRALIA LTD PTY
Responsible party
Sponsor
First posted
Jul 14, 2026
Start date
Aug 2026 (estimated)
Primary completion
Sep 2028 (estimated)
Completion
Nov 2028 (estimated)
Last update
Jul 21, 2026

Study contacts

Li Zhang
Contact
zhangli@syscc.org.cn
86-020-8743990
Li Zhang
principal investigator · Sun Yat-Sen University Cancer Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion